Replimune fi­nal­ly has its eu­re­ka mo­ment. Af­ter two re­jec­tions, pub­lic clash­ing with the pre­vi­ous FDA lead­ers and a closed-door meet­ing with the White House, the Mass­a­chu­setts biotech on Thurs­day re­ceived ac­cel­er­at­ed ap­proval for its ad­vanced melanoma treat­ment, RP1...